Immunohistochemical detection of P-glycoprotein in various subtypes of canine lymphomas

• Autorzy: Sokolowska J. , Urbanska K. , Gizinski S. , Zabielska K. , Lechowski R.
• Języki publikacji: EN

Abstrakty

EN

Combination chemiotherapy is the current standard of care for dogs with lymphoma. Multidrug resistance is one of the most important factors contributing to the efficacy of chemiotherapy. The major protein responsible for this phenomenon is P-glycoprotein. Little is known about P-glycoprotein expression in particular subtypes of lymphomas. The aim of the study was evaluation of P-glycoprotein expression in various subtypes of canine lymphomas. Positive reaction with P-glycoprotein was found in 12/25 cases of various morphological subtypes of lymphomas, however, in 3/11 lymphomas the percentage of positively weakly stained cells was <10% and those tumors were also considered negative. Tumors with 10-50% P-glycoprotein positive cells were found in single cases of centroblastic and centroblastic-centrocytic tumors. In 5 lymphomas P-glycoprotein expression exceeded 50% of tumor cells. Those cases were found among centroblastic, centroblastic-centrocytic, lymphoblastic and Burkitt-like subtypes. Positive reaction was observed mainly in the cell cytoplasm, however, in some cases prominent perinuclear dot-like staining pattern was found. In 2 cases focal staining pattern comprised dominant type of immunolabelling. Among all lymphomas containing P-glycoprotein positive cells intensity of imunolabelling was assessed as weak (6/25), moderate (2/25) and strong (3/25). Our results indicate that P-glycoprotein expression is present in nearly one third of newly diagnosed canine lymphomas of different morphological subtypes including those most commonly occurring, such as cenroblastic lymphomas. Hence, determination of P-glycoprotein expression at the time of diagnosis could provide valuable information for the design of treatment protocols. Moreover, our results have shown that P-glycoprotein expression in canine tumors could be located in Golgi-zone.

• Wydawca: -
• Czasopismo: Polish Journal of Veterinary Sciences
• Rocznik: 2015
• Tom: 18
• Numer: 1
• Opis fizyczny: p.123-130,ref.

Twórcy

autor

Sokolowska J.

• Department of Morphological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences – SGGW, Nowoursynowska 159, 02-776 Warsaw, Poland

autor

Urbanska K.

• Department of Morphological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences – SGGW, Nowoursynowska 159, 02-776 Warsaw, Poland

autor

Gizinski S.

• Department of Large Animal Diseases with Clinic, Faculty of Veterinary Medicine, Warsaw University of Life Sciences – SGGW, Nowoursynowska 100, 02-797 Warsaw, Poland

autor

Zabielska K.

• Departament of Small Animal Diseases with Clinic, Faculty of Veterinary Medicine, Warsaw University of Life Sciences – SGGW, Nowoursynowska 159c, 02-776 Warsaw, Poland

autor

Lechowski R.

• Departament of Small Animal Diseases with Clinic, Faculty of Veterinary Medicine, Warsaw University of Life Sciences – SGGW, Nowoursynowska 159c, 02-776 Warsaw, Poland

Bibliografia

• Arceci RJ (1993) Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81: 2215-2222.
• Axiotis CA, Monteagudo C, Merino MJ, LaPorte N, Neumann RD (1991) Immunohistochemical detection of P-glycoprotein in endometrial adenocarcinoma. Am J Pathol 138: 799-806.
• Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Weinstein R (1996) Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 56: 3010-3020.
• Bergman PJ, Ogilvie GK, Powers BE (1996) Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma. J Vet Intern Med 10: 354-359.
• Campos M, Ducatelle R, Kooistra HS, Rutteman G, Duchateau L, Polis I, Daminet S (2014) Immunohistochemical expression of potential therapeutic targets in canine thyroid carcinoma. J Vet Intern Med 28: 564-570.
• Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287.
• Dhaliwal RS, Kitchell BE, Ehrhart E, Valli VE, Dervisis NG (2013) Clinicopathologic significance of histologic grade, pgp, and p53 expression in canine lymphoma. J Am Anim Hosp Assoc 49: 175-184.
• Flood-Knapik KE, Durham AC, Gregor TP, Sanchez MD, Durney ME, Sorenmo KU (2013) Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma. Vet Comp Oncol 11: 272-286.
• Georges E, Bradley G, Gariepy J, Ling V (1990) Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci U S A 87: 152-156.
• Ginn PE (1996) Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues. Vet Pathol 33: 533-541.
• Hifumi T, Miyoshi N, Kawaguchi H, Nomura K, Yasuda N (2010) Immunohistochemical detection of proteins associated with multidrug resistance to anti-cancer drugs in canine and feline primary pulmonary carcinoma. J Vet Med Sci 72: 665-668.
• Jamroziak K, Smolewski P, Cebula B, Szmigielska-Kaplon A, Darzynkiewicz Z, Robak T (2004) Relation of P-glycoprotein expression with spontaneous in vitro apoptosis in B-cell chronic lymphocytic leukemia. Neoplasma 51: 181-187.
• Jillella AP, Murren JR, Hamid KK, Longley BJ, Edelson RL, Cooper DL (2000) P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma. Cancer Invest 18: 609-613.
• Kaczorowski S, Ochocka M, Aleksandrowicz R, Kaczorowska M, Matysiak M, Karwacki M (1996) Expression of P-Glycoprotein in Children and Adults with Leukemia - Correlation with Clinical Outcome. In: Hiddemann W, Buchner Th, Wormann B, Ritter J, Creutzig U, Plunkett W, Keating MJ (eds) Acute Leukemias V Experimental Approaches and Management of Refractory Diseases. 1 st ed., Springer-Verlag Berlin Heidelberg, pp 101-107.
• Kim NH, Hwang YH, Im KS, Kim JH, Chon SK, Kim HY, Sur JH (2012) P-glycoprotein expression in canine mammary gland tumours related with myoepithelial cells. Res Vet Sci 93: 1346-1352.
• Lee JJ, Hughes CS, Fine RL, Page RL (1996) P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer 77: 1892-1898.
• Li B, Zhong MZ, Tang TF, Liu W, Huang J (2007) Correlation of cyclooxygenase-2 expression to P-glycoprotein expression in B-cell non-Hodgkin's lymphoma. Ai Zheng 26: 851-855.
• Liang JA, Shiau YC, Yang SN, Lin FJ, Kao A, Lee CC (2002) Prediction of chemotherapy response in untreated malignant lymphomas using technetium-99m methoxyisobutylisonitrile scan: comparison with P-glycoprotein expression and other prognostic factors. A preliminary report. Jpn J Clin Oncol 32: 140-145.
• Marie JP (1999) Drug resistance and its modifications in haematological malignancies. In: Degos L, Linch DC, Löwenberg B (eds) Textbook of Malignant Haematology. 1 st ed., Martin Dunitz Ltd, London, pp 299-314.
• Martinez M, Modric S, Sharkey M, Troutman L, Walker L, Mealey K (2008) The pharmacogenomics of P-glycop-rotein and its role in veterinary medicine. J Vet Pharmacol Ther 31: 285-300.
• Molinari A, Calcabrini A, Meschini S, Stringaro A, Del Bufalo D, Cianfriglia M, Arancia G (1998) Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells. Int J Cancer 75: 885-893.
• Moore AS, Leveille CR, Reimann KA, Shu H, Arias IM (1995) The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Invest 13: 475-479.
• Moulton JE, Harvey JW (1990) Tumors of lymphoid and hematopoetic tissue. In: Moulton JE (ed) Tumors of Domestic Animals. 3 rd ed., University of California Press, California, pp 231-301.
• Nooter K, Herweijer H (1991) Multidrug resistance (mdr) genes in human cancer. Br J Cancer 63: 663-669.
• O'Brien JP, Cordon-Cardo C (1991) On the origins of clinical drug resistance. Semin Cancer Biol 2: 227-233.
• Ohsawa M, Ikura Y, Fukushima H, Shirai N, Sugama Y, Suekane T, Hirayama M, Hino M, Ueda M (2005) Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 68: 422-431.
• Plasschaert SL, Vellenga E, de Bont ES, van der Kolk DM, Veerman AJ, Sluiter WJ, Daenen SM, de Vries EG, Kamps WA (2003) High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children. Leuk Lymphoma 44: 85-95.
• Ponce F, Marchal T, Magnol JP, Turinelli V, Ledieu D, Bonnefont C, Pastor M, Delignette ML, Fournel-Fleury C (2010) A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Vet Pathol 47: 414-433.
• Rao VV, Anthony DC, Piwnica-Worms D (1994) MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res 54: 1536-1541.
• Rujirojindakul P, Aiempanakit K, Kayasut K, Lekhakula A, Sriplung H (2011) No Prognostic Impact of p53 and P-Glycoprotein Expression in Patients with Diffuse Large B-Cell Lymphoma. ISRN Oncol 2011: 670358, doi 10.5402/2011/670358.
• Saglam A, Hayran M, Uner AH (2008) Immunohistochemical expression of multidrug resistance proteins in mature T/NK-cell lymphomas. APMIS 116: 791-800.
• Sai Y, Nies AT, Arias IM (1999) Bile acid secretion and direct targeting of mdr1-green fluorescent protein from Golgi to the canalicular membrane in polarized WIF-B cells. J Cell Sci 112: 4535-4545.
• Shiozawa E, Yamochi-Onizuka T, Yamochi T, Yamamoto Y, Naitoh H, Kawakami K, Nakamaki T, Tomoyasu S, Kushima M, Ota H (2003) Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma: immunohistological study of the transformation using CD21, p53, Ki-67, and P-glycoprotein. Pathol Res Pract 199: 293-302.
• Teng SP, Hsu WL, Chiu CY, Wong ML, Chang SC (2012) Overexpression of P-glycoprotein, STAT3, phospho-STAT3 and KIT in spontaneous canine cutaneous mast cell tumours before and after prednisolone treatment. Vet J 193: 551-556.
• Uozurmi K, Nakaichi M, Yamamoto Y, Une S, Taura Y (2005) Development of multidrug resistance in a canine lymphoma cell line. Res Vet Sci 78: 217-224.
• Van der Heyden S, Vercauteren G, Daminet S, Paepe D, Chiers K, Polis I, Waelbers T, Hesta M, Schauvliege S, Wegge B, Ducatelle R (2011) Expression of P-glycoprotein in the intestinal epithelium of dogs with lymphoplasmacytic enteritis. J Comp Pathol 145: 199-206.
• Weinstein RS, Kuszak JR, Jakate SM, Lebovitz MD, Kluskens LF, Coon JS (1990) ABO blood type predicts the cytolocalization of anti-P-glycoprotein monoclonal antibody reactivity in human colon and ureter. Hum Pathol 21: 949-958.

Identyfikatory

DOI

10.1515/pjvs-2015-001